Literature DB >> 31657677

The Promise of miRNA Replacement Therapy for Hepatocellular Carcinoma.

Mahmoud Elhefnawi1,2, Zeinab Salah1, Bangly Soliman1.   

Abstract

Hepatocellular carcinoma is a devastating tumor which accounts for death mortality rate 94% globally, and about 780,000 new cases each year. Tumor suppressor miRNAs represent a class of noncoding RNAs, which exhibit decreased or inhibited expression in the case of carcinogenesis. Therefore, the replacement of these molecules leads to post-transcriptional regulation of tens to hundreds of oncogenic targets and limiting the tumor. Interestingly, there is a group of tumor silencer miRNAs that have been highlighted in HCC and herein, our review will discuss the prominent examples of these miRs in terms of their efficient delivery using vectors, nano-delivery systems, their successful models either in vitro or in vivo and pre-clinical trials. Collectively, tumor suppressor miRNAs can act as novel therapeutics for HCC and more studies should be directed towards these promising therapeutics. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  RNA therapeutics; chronic infection; gene therapy; hepatocellular carcinoma; nanodelivery; tumor suppressor miRNAs.

Year:  2019        PMID: 31657677     DOI: 10.2174/1566523219666191023101433

Source DB:  PubMed          Journal:  Curr Gene Ther        ISSN: 1566-5232            Impact factor:   4.391


  2 in total

1.  LXR activation potentiates sorafenib sensitivity in HCC by activating microRNA-378a transcription.

Authors:  Zhongjie Lin; Shunjie Xia; Yuelong Liang; Lin Ji; Yu Pan; Shi Jiang; Zhe Wan; Liye Tao; Jiang Chen; Chengping Lin; Xiao Liang; Junjie Xu; Xiujun Cai
Journal:  Theranostics       Date:  2020-07-11       Impact factor: 11.556

2.  Circ-RNF13, as an oncogene, regulates malignant progression of HBV-associated hepatocellular carcinoma cells and HBV infection through ceRNA pathway of circ-RNF13/miR-424-5p/TGIF2.

Authors:  Yan Chen; Shuhua Li; Yinbin Wei; Zhihong Xu; Xiongfei Wu
Journal:  Bosn J Basic Med Sci       Date:  2021-10-01       Impact factor: 3.363

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.